Ursula Fritsch, President of East Bay Bio, has more than 30 years of experience in the biopharmaceutical industry, supporting regulatory activities from asset acquisition through phase 3 and market approval of small molecules and complex biologics. Dr. Fritsch has developed strategies for a myriad of regulatory interactions and meeting across many geographies including, the US/Canada, Europe, Asia and Australia/New Zealand and has written and filed numerous INDs, BLAs and NDAs over the course of her career.
Dr. Fritsch has lead the regulatory development team across many companies as part of the executive management team. She has worked in diverse therapeutic areas such as immunologic/oncology, rare diseases, cardiovascular and endocrine disease.
Dr. Fritsch holds a Doctorate of Pharmacy from Creighton University.